Spyre Therapeutics, Inc. $SYRE Shares Sold by TD Asset Management Inc

TD Asset Management Inc decreased its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 36.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 72,368 shares of the company’s stock after selling 41,600 shares during the period. TD Asset Management Inc owned about 0.12% of Spyre Therapeutics worth $1,213,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. California State Teachers Retirement System raised its holdings in Spyre Therapeutics by 1.8% in the 2nd quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock worth $497,000 after purchasing an additional 603 shares during the period. F m Investments LLC grew its stake in Spyre Therapeutics by 1.4% in the 2nd quarter. F m Investments LLC now owns 52,546 shares of the company’s stock valued at $787,000 after acquiring an additional 702 shares during the period. AlphaQuest LLC increased its holdings in Spyre Therapeutics by 30.8% in the 2nd quarter. AlphaQuest LLC now owns 4,174 shares of the company’s stock worth $62,000 after acquiring an additional 983 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Spyre Therapeutics by 25.8% during the second quarter. Ameritas Investment Partners Inc. now owns 5,091 shares of the company’s stock worth $76,000 after acquiring an additional 1,045 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Spyre Therapeutics by 9.7% in the second quarter. ProShare Advisors LLC now owns 12,479 shares of the company’s stock valued at $187,000 after purchasing an additional 1,101 shares during the period. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Spyre Therapeutics Trading Down 1.0%

Shares of SYRE opened at $40.59 on Friday. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $45.76. The firm has a market capitalization of $3.19 billion, a P/E ratio of -19.51 and a beta of 3.09. The firm has a 50-day moving average price of $35.04 and a 200 day moving average price of $26.93.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Thursday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Equities research analysts predict that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Spyre Therapeutics

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $42.19, for a total value of $632,850.00. Following the sale, the chief executive officer owned 642,540 shares in the company, valued at $27,108,762.60. The trade was a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott L. Burrows sold 2,500 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $40.65, for a total value of $101,625.00. Following the transaction, the chief financial officer owned 97,994 shares of the company’s stock, valued at approximately $3,983,456.10. This represents a 2.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 47,500 shares of company stock valued at $1,686,675. 15.43% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. JonesTrading raised shares of Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research note on Monday, December 1st. Wall Street Zen lowered Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Citigroup started coverage on Spyre Therapeutics in a report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price objective on the stock. Wells Fargo & Company upped their target price on shares of Spyre Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Finally, BTIG Research reissued a “buy” rating and issued a $70.00 price target on shares of Spyre Therapeutics in a research note on Friday, February 20th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Spyre Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $53.44.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.